| Fiscal period | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|
| Period End Date | 9/30/2021 | 9/30/2020 | 9/30/2019 | 9/30/2018 | 9/30/2017 | 9/30/2016 | 9/30/2015 | 9/30/2014 | 9/30/2013 | 9/30/2012 |
|---|
| Sales | 317.90 | 253.67 | 201.01 | 213.57 | 200.77 | 196.08 | 194.83 | 188.83 | 188.69 | 172.71 |
| Total Revenues | 317.90 | 253.67 | 201.01 | 213.57 | 200.77 | 196.08 | 194.83 | 188.83 | 188.69 | 172.71 |
| Cost of sales | 116.75 | 97.42 | 82.29 | 82.54 | 76.48 | 68.87 | 72.95 | 71.59 | 67.64 | 63.66 |
| Cost of sales: Sale of product | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cost of sales: Inventory impairment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Cost of sales - Plant Consolidation | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Gross Profit | 201.15 | 156.25 | 118.73 | 131.03 | 124.29 | 127.21 | 121.88 | 117.24 | 121.04 | 109.05 |
| Goodwill impairment charge | -- | -- | -- | -- | 6.63 | -- | -- | -- | -- | -- |
| Research and development | 23.91 | 23.73 | 17.76 | 16.61 | 16.04 | 14.19 | 12.61 | 12.55 | 10.79 | 10.28 |
| Acquired in-process research and development | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| General and Administrative | 49.54 | 44.35 | 34.04 | 35.76 | 31.10 | 29.43 | 27.62 | 27.39 | 30.52 | 26.37 |
| Sales and marketing | 26.78 | 26.49 | 28.00 | 34.03 | 32.39 | 30.06 | 25.60 | 24.91 | 22.42 | 22.09 |
| Sales and marketing leadership reorganization | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Merger integration costs | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| European restructuring costs | -- | -- | -- | -- | -- | 0.68 | -- | -- | -- | -- |
| Costs of abandoned acquisition | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Restructuring Costs | -- | 0.69 | 2.84 | 8.71 | 0.13 | -- | -- | -- | -- | -- |
| Bioline Group transaction costs | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Product recall costs | (5.60) | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Costs and asset impairment charges related to FDA matters | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Litigation costs | -- | -- | -- | (4.35) | (0.63) | -- | -- | -- | -- | -- |
| Acquisition-related costs | (0.39) | (3.89) | (1.81) | -- | -- | (1.48) | -- | -- | -- | -- |
| Plant consolidation costs | -- | -- | -- | -- | -- | -- | -- | -- | -- | (1.01) |
| Change in fair value of contingent consideration obligation | 0.91 | 6.29 | -- | -- | -- | -- | -- | -- | -- | -- |
| Selected legal costs | (2.80) | (2.08) | (1.58) | -- | -- | -- | -- | -- | -- | -- |
| Total Operating Expenses | 108.11 | 94.92 | 86.03 | 99.45 | 86.91 | 75.83 | 65.82 | 64.85 | 63.73 | 59.75 |
| Operating Income (loss) | 93.03 | 61.32 | 32.70 | 31.58 | 37.38 | 51.38 | 56.06 | 52.39 | 57.31 | 49.30 |
| Interest expense | 1.88 | 2.63 | 1.95 | 1.52 | 1.64 | 0.90 | -- | -- | -- | -- |
| Interest income | -- | 0.14 | 0.68 | 0.42 | 0.17 | 0.07 | 0.02 | 0.03 | 0.04 | 0.04 |
| Other | (1.71) | 0.46 | 0.12 | (0.10) | 0.52 | 0.10 | (1.02) | (0.31) | 0.00 | 0.38 |
| RADx grant income | 1.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Earnings before income taxes | 90.45 | 59.29 | 31.56 | 30.38 | 36.43 | 50.64 | 55.06 | 52.11 | 57.36 | 49.72 |
| Current : State and local | 1.16 | 1.17 | 0.83 | 1.07 | 1.90 | 2.42 | 2.24 | 1.76 | 2.01 | 1.52 |
| Income tax (benefit) provision | 19.04 | 13.11 | 7.18 | 6.53 | 14.87 | 18.42 | 19.52 | 17.37 | 19.33 | 16.35 |
| Foreign | -- | -- | -- | 0.40 | 0.80 | 0.95 | 0.89 | 0.28 | 0.61 | 1.02 |
| Federal: Current provision | 4.43 | 1.17 | 5.00 | 6.03 | 11.26 | -- | 16.15 | 15.02 | -- | -- |
| Federal: Fixed asset basis differences and depreciation | -- | -- | -- | 0.41 | (0.18) | (0.05) | 0.05 | 0.11 | 0.12 | 0.00 |
| Federal: Intangible asset basis differences and amortization | -- | -- | -- | (4.05) | (1.16) | (0.74) | (0.42) | (0.21) | (0.34) | (0.35) |
| Federal: Currently non-deductible expenses and reserves | -- | -- | -- | 1.21 | 0.88 | (0.69) | 0.22 | 0.05 | (0.43) | (0.40) |
| Federal: Stock based compensation | -- | -- | -- | 1.38 | (0.64) | 0.13 | 0.13 | 0.06 | (0.28) | (0.60) |
| Federal: Other, net | -- | -- | -- | (0.15) | 0.10 | 0.18 | 0.02 | 0.07 | 0.04 | 0.07 |
| Federal: Currency translation | 16.31 | 10.19 | 1.92 | -- | -- | -- | -- | -- | -- | -- |
| Federal: Net operating loss carryforwards | -- | -- | -- | 0.06 | 1.83 | -- | -- | -- | -- | -- |
| Federal: Abandoned acquisition costs | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Federal: Tax contingency reserve adjustment | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Federal: Tax credit carryforwards | -- | -- | -- | 0.18 | 0.07 | 0.04 | 0.25 | 0.23 | (0.72) | -- |
| Provision (benefit) for income taxes -Federal -Deferred | (2.60) | 0.74 | (0.48) | -- | -- | -- | -- | -- | -- | -- |
| Provision(benefit) for income taxes -Foreign -Deferred | (0.26) | (0.17) | (0.10) | -- | -- | -- | -- | -- | -- | -- |
| Net Income (loss) Available to Common Shareholders | 71.41 | 46.19 | 24.38 | 23.85 | 21.56 | 32.23 | 35.54 | 34.74 | 38.03 | 33.37 |
| Net Earnings Per Share (Basic) | 1.65 | 1.08 | 0.57 | 0.56 | 0.51 | 0.77 | 0.85 | 0.84 | 0.92 | 0.81 |
| Net Earnings Per Share (Diluted) | 1.62 | 1.07 | 0.57 | 0.56 | 0.51 | 0.76 | 0.85 | 0.83 | 0.91 | 0.80 |
| Weighted Average Shares Outstanding (Basic) | 43.26 | 42.86 | 42.57 | 42.33 | 42.19 | 42.01 | 41.66 | 41.46 | 41.23 | 41.08 |
| Weighted Average Shares Outstanding (Diluted) | 44.01 | 43.17 | 42.90 | 42.75 | 42.57 | 42.39 | 42.01 | 41.91 | 41.90 | 41.61 |